SCHEMBL3473808

SCHEMBL3473808

FC(F)(F)c1cc(-c2ccc(OCc3ccccc3)cc2)n(-c2ccccc2Cl)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.55
NR1H2 P55055 3/20 0.55
NR1H3 Q13133 3/20 0.55
NR3C2 P08235 1/20 0.48
MDM2 Q00987 2/20 0.47
PTGS1 P23219 6/20 0.47
PTGS2 P35354 6/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
THPO P40225 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473891 0.89 NR1H2 (0.57) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL2257733 0.87 GAA (0.42) RXRANR1H2NR1H3NR3C2MDM2
SCHEMBL3471970 0.86 RXRA (0.56) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3473190 0.85 RXRA (0.56) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3471319 0.82 MAPT (0.51) RXRANR1H2NR1H3
SCHEMBL2260114 0.82 RXRA (0.49) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3477579 0.82 RXRA (0.55) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3471669 0.81 RXRA (0.56) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL3470766 0.81 RXRA (0.64) RXRANR1H2NR1H3NR3C2PTGS1
SCHEMBL2255961 0.80 NR1H2 (0.41) RXRANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.